Drilldown: Medicines

Codeine (2)

Other values:

Search

None (29) · (multiple, generic dominant) (1) · Alfenta (1) · Darvon (1) · Demerol (1) · Dilaudid (1) · Dolophine (1) · Duragesic (1) · DXM (1) · DXO (1) · Heroin (1) · Imitrex (oral, injectable, nasal), Tosymra (nasal spray), Onzetra Xsail (nasal powder), Zembrace SymTouch (low-dose autoinjector), Sumavel DosePro (needle-free SC) (1) · Krokodil (1) · Maxalt (tablet), Maxalt-MLT (orally disintegrating tablet) (1) · Nubain (1) · Nucynta (1) · O-DSMT (1) · Opana (1) · Spravato (1) · Stablon (1) · Stadol (1) · Suboxone (1) · Sufenta (1) · Talwin (1) · Treximet (1) · Ultiva (1) · Vicodin (1)

Research material · Classic Psychedelic · Stimulant · Opioid · Sedative-Hypnotic · Phenethylamine · Tryptamine · Benzodiazepine · Botanical · [[:Category:Antihypertensives|Antihypertensive]] · Dissociative · Anticonvulsant · Antidepressant · Plant Medicine · Analgesic · Antipsychotic · Antiparkinsonian · Empathogen · Neuroleptic · Cathinone

Other values:

Search

Potent mu-opioid receptor agonist (6) · Mu-opioid receptor agonist (4) · None (3) · NMDA antagonist (3) · NMDA antagonist; sigma receptor agonist (2)

Other values:

Search

None (50) · Mild to moderate pain; cough suppression (low-dose). (1) · Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020). (1) · '"`UNIQ--vote-00000011-QINU`"' (1) · '"`UNIQ--vote-00000013-QINU`"', '"`UNIQ--vote-00000014-QINU`"' (1) · '"`UNIQ--vote-000015D0-QINU`"' (1)

None (50) · 1 tablet (85/500 mg sumatriptan/naproxen) PO at migraine onset; may repeat after 2 hours if needed; maximum 2 tablets per 24 hours (1) · 5-10 mg PO at migraine onset; may repeat after 2 hours, maximum 30 mg/24 hours (1) · Adult: 15–60 mg every 4 hours as needed. (1) · Induction (TRD): 56 mg intranasal twice weekly × 4 weeks. Maintenance: 56-84 mg once weekly × 4 weeks, then 56-84 mg every 1-2 weeks. For acute suicidality: 84 mg twice weekly × 4 weeks. Administered under medical supervision in REMS-certified site. (1) · Oral: 50-100 mg at migraine onset, may repeat in 2 hours if needed. SC: 6 mg, may repeat in 1 hour. Nasal: 5-20 mg per nostril, may repeat in 2 hours (1)

None (50) · 28 mg/device (each dose uses 2 devices) (1) · 85 mg sumatriptan / 500 mg naproxen sodium tablets; lower-dose 10/60 mg pediatric (Treximet pediatric) (1) · Oral tablets 25, 50, 100 mg; SC injection 4, 6 mg autoinjector; needle-free SC 6 mg (Sumavel); nasal spray 5, 20 mg; nasal powder 22 mg (Onzetra Xsail); low-dose autoinjector 3 mg (Zembrace SymTouch) (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1) · Tablets 5, 10 mg; ODT (Maxalt-MLT) 5, 10 mg (1)

None (50) · 2 tablets per 24 hours; ≤4 days per month to avoid medicine-overuse headache (1) · 200 mg/day (oral); 12 mg/day (SC); 40 mg/day (nasal spray); 44 mg/day (Onzetra) (1) · 30 mg/24 hours (1) · 360 mg/day (1) · 84 mg per session (1)

None (50) · intranasal (1) · Intranasal (under direct medical supervision) (1) · Oral (3) · PO (only formulation marketed in the US). (1) · subcutaneous (1)

None (50) · 10 minutes (SC); 15-30 minutes (nasal); 30-60 minutes (oral) (1) · 30 minutes for migraine relief (1) · 30–60 min (PO) (1) · Headache relief at 30-60 minutes (1) · Within hours of first administration (1)

None (50) · 2-4 hours; headache recurrence rate ~20-30% within 24 hours (1) · 4-6 hours; headache recurrence is common (1) · 4-8 hours (1) · 4–6 hours (1) · Acute effect ~24 hours; cumulative effect builds with repeated dosing (1)

None (50) · 2 hours'"`UNIQ--ref-00000015-QINU`"' (1) · 2-3 hours'"`UNIQ--ref-00000012-QINU`"' (1) · 2.5–3 hours (1) · Sumatriptan ~2.5 hours; naproxen 12-15 hours'"`UNIQ--ref-000015D1-QINU`"' (1) · ~7-12 hours (1)

None (50) · Sumatriptan ~15% (oral; substantial first-pass); naproxen ~95%'"`UNIQ--ref-000015D2-QINU`"' (1) · ~14% (oral; substantial first-pass); ~97% (subcutaneous); ~17% (nasal)'"`UNIQ--ref-00000016-QINU`"' (1) · ~45% (oral; substantially higher than sumatriptan's ~14%)'"`UNIQ--ref-00000013-QINU`"' (1) · ~48% intranasal (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1)

None (50) · Avoid; may cause fetal harm (1) · Avoid; NSAID-class restriction after 20 weeks (FDA 2020) and limited triptan pregnancy data.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Limited human data; pregnancy registry data have been broadly reassuring across the triptan class.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Limited human data; pregnancy registry data have been broadly reassuring relative to baseline malformation rates.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)

None (50) · Rx, Schedule III (US). REMS program required. (1) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1) · [[USLegal:Prescription only|Rx-only]] in US (2) · [[USLegal:Prescription only|Rx-only]] in US. NSAID-class '''Boxed Warning''' for CV thrombotic events and GI bleeding; triptans contraindicated in coronary artery disease, peripheral vascular disease, uncontrolled hypertension, and recent ergot or MAOI use'"`UNIQ--ref-000015D3-QINU`"' (1)